WASHINGTON, DC and DENVER, JANUARY 6, 2021 – The Global Liver Institute (GLI), the only patient-led liver health nonprofit operating internationally, in partnership with TriSalus Life...
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
POLICY PERSPECTIVE In the past, efforts in liver advocacy were siloed by individual liver disease lessening their impact and limiting their effectiveness at shaping national health policy. In 2021...
On February 4, 2022 10 AM ET, Global Liver Institute led an Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) on Primary Biliary Cholangitis (PBC). This online event is open to the...
Donna R. Cryer, JD, President and CEO, Honored with Awards from the American Association for the Study of Liver Diseases (AASLD) and Global Genes for leadership in connecting, empowering, inspiring...
POLICY PERSPECTIVE The liver advocacy community — with the GLI Liver Action Network leading the way — has elevated patient voices through a variety of initiatives throughout September and October....
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
Dear Colleague: October is Liver Cancer Awareness Month. This represents an opportunity to draw attention to the global burden of liver cancer and to highlight the various public health...
On November 4th at 10 AM ET, Global Liver Institute led an Externally Led Patient-Focused Drug Development Meeting on NASH for the FDA. This online event is open to the public with registration...
(Washington, DC, Friday, October 22, 2021)—Global Liver Institute (GLI) CEO and President, Donna R. Cryer, JD, yesterday applauded the actions of U.S. Representative Nydia Velázquez...
Recent News
Rural Communities at Risk: Global Liver Institute Champions Awareness for Rare Liver Diseases(Washington, DC, February 1, 2025) – As rural healthcare access shrinks across the United States and remains limited worldwide, Global Liver Institute (GLI) is shining a...
Global Liver Institute Supports CMS Coverage of Obesity Medications(Washington, D.C., January 22, 2025) – Global Liver Institute (GLI) was very pleased to see the U.S. Centers for Medicare and Medicaid Services (CMS) take the step towards expanding coverage for...
Breaking: Global Liver Institute Statement on U.S. End-of-Year Health Package(Washington, D.C., December 17, 2024) – Global Liver Institute (GLI) celebrates the release of bill text last night for a continuing resolution (CR) for FY2025 from the U.S. House of...
The Case for Universal Access to Hepatitis C DAA Treatment for Your PatientsHepatitis C is a viral infection of the liver caused by the hepatitis C virus (HCV) and spread through blood-to-blood exposure. The majority of people exposed to HCV develop chronic infection,...
Can Blood Tests Help Predict Liver Transplant Outcomes? As we conclude this year, the Pediatric and Rare Liver Diseases team is reflecting on the incredible progress made by our council and patient organizations in 2024. We were so proud to see so...
